MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Epidemiological analysis of autosomal dominant chorea in Eastern Algeria

Y. Mecheri, D. Satta, F. Serradj (Constantine, Algeria)

Meeting: 2023 International Congress

Abstract Number: 889

Keywords: Chorea (also see specific diagnoses, Huntingtons disease, etc): Clinical features

Category: Huntington's Disease

Objective: We aim to analyze the main epidemiological characteristics of individuals having a Huntington disease phenotype in Eastern Algeria population.

Background: Huntington’s disease (HD) is the most frequent autosomal dominant chorea in the world, it is caused by an abnormal and unstable repeat expansion of CAG triplets in the HTT gene [1]. HD usually manifests in the adulthood by chorea, cognitive, psychiatric and behavioral impairments chorea [2]–[4]. There is no prior clinical or epidemiological study of HD or of other hereditary chorea in the Algerian population limiting the patients access to care.

Method: We performed a cross-sectional and retrospective analysis of the epidemiological data collected between 2015 and 2022 in Benbadis Constantine University Hospital. We included 45 symptomatic patients from 4 families originating from Eastern Algeria and having a HD phenotype without the presence of signs suggesting other etiologies.

Results: The frequency was 1.25 per 100 000 inhabitants lower than the world average frequency (2.7 per 100,000 inhabitants [5] which can be explained, as in the other African cohorts, by poor access to care [6]. The sex ratio was 2.21, whereas it is 1 in the literature, which may be explained by a fear of social stigmatization of affected women. At the time of inclusion 25 patients are alive with an average age of 49.6 years (23-69 years), the most represented age group is between 40-60 years. The age of motor onset was variable between 21 and 71 years, it is between 40 and 60 years in 62.22% of cases and between 20 and 40 years in a third of cases. This intergenerational variability is related to anticipation phenomena with paternal transmission [7]. The inter-familial variability is probably related to a different number of CAG repeats and/or the effect of different genetic modifiers [8]–[11]. The mean age of death was 56.42 years and is similar to literature data [12]. Genetic testing is needed to confirm the HD diagnosis or of other HD phenocopies (HLD2, C9orf72….).

Conclusion: More efforts need to be made to collect more information, include more families and perform genetic analysis of patients and suspected cases. The goal is to create a national cohort including all the epidemiological, genetic and clinical data of the Algerian population and to establish local management recommendations.

Fig 01 Family trees of the included patients

Fig 02 Age at inclusion in the study

References: [1] M. Macdonald, “A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes,” Cell, vol. 72, no. 6, pp. 971–983, Mar. 1993, doi: 10.1016/0092-8674(93)90585-E.
[2] C. A. Ross et al., “Huntington disease: natural history, biomarkers and prospects for therapeutics,” Nat. Rev. Neurol., vol. 10, no. 4, pp. 204–216, Apr. 2014, doi: 10.1038/nrneurol.2014.24.
[3] E. R. Dorsey et al., “Natural history of Huntington disease,” JAMA Neurol., vol. 70, no. 12, pp. 1520–1530, Dec. 2013, doi: 10.1001/jamaneurol.2013.4408.
[4] A. Barbeau, R. C. Duvoisin, F. Gerstenbrand, J. P. Lakke, C. D. Marsden, and G. Stern, “Classification of extrapyramidal disorders. Proposal for an international classification and glossary of terms,” J. Neurol. Sci., vol. 51, no. 2, pp. 311–327, Aug. 1981, doi: 10.1016/0022-510x(81)90109-x.
[5] M. D. Rawlins et al., “The Prevalence of Huntington’s Disease,” Neuroepidemiology, vol. 46, no. 2, pp. 144–153, 2016, doi: 10.1159/000443738.
[6] M. R. Hayden, J. M. MacGregor, and P. H. Beighton, “The prevalence of Huntington’s chorea in South Africa,” South Afr. Med. J. Suid-Afr. Tydskr. Vir Geneeskd., vol. 58, no. 5, pp. 193–196, Aug. 1980.
[7] N. G. Ranen et al., “Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease,” Am. J. Hum. Genet., vol. 57, no. 3, pp. 593–602, Sep. 1995.
[8] J.-M. Lee et al., “Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease,” Cell, vol. 162, no. 3, pp. 516–526, Jul. 2015, doi: 10.1016/j.cell.2015.07.003.
[9] M. Ciosi et al., “A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes,” EBioMedicine, vol. 48, pp. 568–580, Oct. 2019, doi: 10.1016/j.ebiom.2019.09.020.
[10] G. E. B. Wright et al., “Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease,” Am. J. Hum. Genet., vol. 104, no. 6, pp. 1116–1126, Jun. 2019, doi: 10.1016/j.ajhg.2019.04.007.
[11] D. J. H. Moss et al., “Identification of genetic variants associated with Huntington’s disease progression: a genome-wide association study,” Lancet Neurol., vol. 16, no. 9, pp. 701–711, Sep. 2017, doi: 10.1016/S1474-4422(17)30161-8.
[12] F. B. Rodrigues et al., “Survival, Mortality, Causes and Places of Death in a European Huntington’s Disease Prospective Cohort,” Mov. Disord. Clin. Pract., vol. 4, no. 5, pp. 737–742, Oct. 2017, doi: 10.1002/mdc3.12502.
[13] R. A. C. Roos, “Huntington’s disease: a clinical review,” Orphanet J. Rare Dis., vol. 5, p. 40, Dec. 2010, doi: 10.1186/1750-1172-5-40.
[14] R. Ghosh and S. J. Tabrizi, “Clinical Features of Huntington’s Disease,” in Polyglutamine Disorders, vol. 1049, C. Nóbrega and L. Pereira de Almeida, Eds. Cham: Springer International Publishing, 2018, pp. 1–28. [Online]. Available: http://link.springer.com/10.1007/978-3-319-71779-1_1

To cite this abstract in AMA style:

Y. Mecheri, D. Satta, F. Serradj. Epidemiological analysis of autosomal dominant chorea in Eastern Algeria [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/epidemiological-analysis-of-autosomal-dominant-chorea-in-eastern-algeria/. Accessed May 22, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/epidemiological-analysis-of-autosomal-dominant-chorea-in-eastern-algeria/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley